AU2002224478A1 - Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke - Google Patents

Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke

Info

Publication number
AU2002224478A1
AU2002224478A1 AU2002224478A AU2447802A AU2002224478A1 AU 2002224478 A1 AU2002224478 A1 AU 2002224478A1 AU 2002224478 A AU2002224478 A AU 2002224478A AU 2447802 A AU2447802 A AU 2447802A AU 2002224478 A1 AU2002224478 A1 AU 2002224478A1
Authority
AU
Australia
Prior art keywords
aminoalkylpyridines
delta2
triazoline
anticonvulsants
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224478A
Inventor
Pankaja K. Kadaba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
K and K Biosciences Inc
Original Assignee
K and K Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K and K Biosciences Inc filed Critical K and K Biosciences Inc
Publication of AU2002224478A1 publication Critical patent/AU2002224478A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002224478A 2000-11-02 2001-11-02 Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke Abandoned AU2002224478A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24493000P 2000-11-02 2000-11-02
US60244930 2000-11-02
US30736001P 2001-07-25 2001-07-25
US60307360 2001-07-25
PCT/US2001/042898 WO2002036119A1 (en) 2000-11-02 2001-11-02 Δ2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke

Publications (1)

Publication Number Publication Date
AU2002224478A1 true AU2002224478A1 (en) 2002-05-15

Family

ID=26936896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224478A Abandoned AU2002224478A1 (en) 2000-11-02 2001-11-02 Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke

Country Status (4)

Country Link
US (3) US6638954B2 (en)
EP (1) EP1343497A4 (en)
AU (1) AU2002224478A1 (en)
WO (1) WO2002036119A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002553B2 (en) * 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
US7610094B2 (en) * 2003-09-18 2009-10-27 Cardiac Pacemakers, Inc. Synergistic use of medical devices for detecting medical disorders
US7591265B2 (en) * 2003-09-18 2009-09-22 Cardiac Pacemakers, Inc. Coordinated use of respiratory and cardiac therapies for sleep disordered breathing
US7575553B2 (en) * 2003-09-18 2009-08-18 Cardiac Pacemakers, Inc. Methods and systems for assessing pulmonary disease
US7662101B2 (en) * 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
US20050142070A1 (en) * 2003-09-18 2005-06-30 Hartley Jesse W. Methods and systems for assessing pulmonary disease with drug therapy control
US7887493B2 (en) * 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US8030332B2 (en) * 2006-02-01 2011-10-04 Merck Sharp & Dohme Corp. Potassium channel inhibitors
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
EP1921071A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
EP2752411A1 (en) * 2013-01-07 2014-07-09 Laboratorios Del Dr. Esteve, S.A. 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797224A (en) * 1955-01-24 1957-06-25 Schenley Ind Inc Process for preparing picolyl secondary amines
US3654290A (en) * 1970-03-27 1972-04-04 Hoffmann La Roche Intermediates for 5-(pyridylalkyl) pyridoindole derivatives
US4511572A (en) 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
US4689334A (en) 1983-03-18 1987-08-25 The University Of Kentucky Research Foundation Triazoline anticonvulsant compounds and compositions
US4618681A (en) 1983-03-18 1986-10-21 The University Of Kentucky Research Foundation Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants
US4610994A (en) * 1984-04-26 1986-09-09 The University Of Kentucky Research Foundation 1,2,3-triazole anticonvulsant drugs
US4874775A (en) * 1985-06-11 1989-10-17 Eli Lilly And Company Agriculturally useful sulfonamides
US4820721A (en) 1988-04-11 1989-04-11 Kadaba Pankaja K 1-aryl-5-(2-oxo-1-pyrrolidinyl)-1,2,3-triazolines as novel anticonvulsants
US5648369A (en) 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
US5942527A (en) * 1997-08-27 1999-08-24 K & K Biosciences, Inc. Hydrazones, hydrazines, semicarbazones and thiosemicarbazones derived from pyridyl ketones as anticonvulsant drugs and excitatory amino acid antagonists
US6083964A (en) * 1998-02-18 2000-07-04 K And K Biosciences, Inc. Optical resolution of racemic aminoalkylpyridine anticonvulsants and (+) aminoalkylpyridine enantiomers as highly potent orally effective anticonvulsant drugs and excitatory amino acid antagonists
US6514687B1 (en) * 1998-12-14 2003-02-04 Vertex Pharmaceuticals (San Diego), Llc Optical molecular sensors for cytochrome P450 activity

Also Published As

Publication number Publication date
US20020111371A1 (en) 2002-08-15
EP1343497A4 (en) 2005-01-26
US6638954B2 (en) 2003-10-28
US20060058357A1 (en) 2006-03-16
EP1343497A1 (en) 2003-09-17
US20040073039A1 (en) 2004-04-15
WO2002036119A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
AU2002224478A1 (en) Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke
HK1066466A1 (en) Pharmaceutical formulations of antineoplastic agents in particular temozolomide processes of making and using the same
HK1079215A1 (en) 17 alpfa-alkyl-17beta-oxy-estrqatrienes, uses thereof and pharmaceutical preparations
IS3023B (en) 3 - ((3R, 4R) -4-methyl-3- [methyl- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -amino] -piperidinyl) -3-oxo-propionitrile as a protein kinase inhibitor
IT1308180B1 (en) SYNTHETIC PEPTIDES HAVING THE ABILITY TO DECREASE SURFACE TENSION AND THEIR USE IN THE PREPARATION OF A SURFACTANT
IL165696A0 (en) Substituted 1,3-diphenykprop-2-en-1-one derivatives and preparation and uses thereof
AU2002245216A1 (en) Imaged nonwoven fabric for imparting an improved aesthetic texture to surfaces
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
DE60131760D1 (en) DEVICE FOR THE ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE ACTIVE IN POWDER FORM
HK1062567A1 (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
ITMI951764A0 (en) ENGINEERED PEPTIDE SYNTHETASES AND THEIR USE FOR THE NON-RIBOSOME PRODUCTION OF PEPTIDES
PL375603A1 (en) Depot formulations of arylheterocyclic active agents in the form of a suspension
IL160190A0 (en) Use of copolymer to produce a galenic form containining a peptide or a protein as active agent
ITBO20010311A0 (en) SYSTEM FOR THE DRYING OF PAINTED SURFACES, IN PARTICULAR VEHICLES AND THEIR DETACHED PARTS, AND PROCEDURE FOR ITS CONTROL
HUP0202842A3 (en) Spherical telithromycin clusters, method for their production and use thereof in the pharmaceutical compositions
PL366614A1 (en) 2 methyl-thieno-benzodiazepine lyophilized formulation
HK1038682A1 (en) Accessary coatable with nail polish and the methodfor using the same
IL164901A0 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
EP1357129A4 (en) Novel physiologically active peptide and use thereof
FR2826366B1 (en) PREPARATION OF MASK ISOCYANATES, IN PARTICULAR MASK POLYISOCYANATES
ZA200410062B (en) Novel adenosine analogues and their use as pharmaceutical agents
EP1172103A3 (en) Combination of 3-iodo-2-propynyl-butylcarbamate esters and one or more hydroxybenzoic acids
EP1450921A4 (en) Improvements in and relating to evaporators background to the invention
IT1284030B1 (en) METHOD FOR THE PRODUCTION OF STABLE AQUEOUS SUSPENSIONS, USEFUL IN PHARMACEUTICAL COMPOSITIONS
IT1317818B1 (en) PROCEDURE FOR THE PRODUCTION OF COMPONENTS FOR INTEGRATORIALIMENTARIES, DIETARY, COSMETIC AND PHARMACEUTICAL FORMULATIONS,